Di-DTPA-LTL

Di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with 111In (indium) and 131I (iodine) . di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled 111In) into the patients[1][2][3].

Product Specifications

UNSPSC

12352005

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/di-dtpa-ltl.html

Solubility

10 mM in DMSO

Smiles

OC(CN(CCN(CC(O)=O)CCN(CC(NCCCC[C@@H](C(N[C@H](CC1=CC=C(O)C=C1)C(N[C@@H](CCCCNC(CN(CCN(CCN(CCC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)=O)C(N)=O)=O)=O)NC(C)=O)=O)CC(O)=O)CC(O)=O)=O

Molecular Formula

C52H82N12O23

Molecular Weight

1243.27

References & Citations

[1]Gruaz-Guyon A, et al. Recent advances in pretargeted radioimmunotherapy. Curr Med Chem. 2005;12 (3) :319-38. |[2]Gautherot E, et al. Therapy for colon carcinoma xenografts with bispecific antibody‐targeted, iodine‐131‐labeled bivalent hapten[J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 1997, 80 (S12) : 2618-2623.|[3]Aarts F, et al. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F (ab′) 2 antibody[J]. Cancer, 2010, 116 (S4) : 1111-1117.